Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Title: Elevated SGPL1 expression increases metabolic rate and reduces survival in adrenocortical carcinoma patients

ABSTRACT: Title: Elevated SGPL1 expression increases metabolic rate and reduces survival in adrenocortical carcinoma patients

PROVIDER: PRJNA786217 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Title: Elevated SGPL1 expression increases metabolic rate and reduces survival in adrenocortical carcinoma patients

Project description:Sphingosine-1-phosphate lyase (SGPL1) catalyses the final step in sphingolipid metabolism (Figure 1), irreversibly degrading the lipid signalling molecule sphingosine-1-phosphate (S1P). Loss-of-function mutations in SGPL1 cause a spectrum of disorders, including primary adrenal insufficiency. Given loss of SGPL1 causes reduced steroidogenesis, while increased steroidogenesis is a hallmark of aggressive adrenocortical carcinomas (ACCs), we hypothesise increased SGPL1 expression might regulate ACCs. We identified a potential novel biomarker in ACCs, whereby increased SGPL1 expression correlates with reduced patient survival. We also saw similar correlation with other sphingolipid enzymes which diminish the ceramide pool, while those that replenish it confer a beneficial patient outcome. Increased SGPL1 expression in a cell model increased their resting proliferation and migration, although no effect on apoptosis was seen. There was a global decrease in the sphingolipid pool, possibly indicating increased flux through this pathway. RNAseq analysis identified an increase in expression of oxidative phosphorylation genes, and this correlated with an increase in basal and maximal glycolysis and oxidative phosphorylation. Finally, we showed that the increase in proliferation in the OE cells is dependent on the presence of metabolic substrates which may be used for anabolism and/or the production of ATP.

2022-12-08 | GSE190177 | GEO

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

Project description:Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

| PRJNA484072 | ENA

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

Project description:Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors

| PRJNA484071 | ENA

Deregulated miRNAs in adrenocortical tumors

Project description:We performed miRNA expression profiling in a series of adrenocortical carcinomas, adrenocortical adenomas and normal adreno cortex using a microarray approach. Significant differentially expressed miRNAs among groups were identified using SAM analysis.

2011-06-01 | GSE22816 | GEO

Study Title > and <

Project description:Study Title > and <

| PRJEB64481 | ENA

title testing 20180524

Project description:title testing 20180524

| PRJEB27053 | ENA

CGH analysis of adrenocortical tumors

Project description:Adrenocortical tumors are common; their prevalence may reach up to 5-7% in pathological series. Most of them are benign and hormonally inactive, however, rare hormone-secreting (aldosterone and cortisol) and malignant forms are associated with significant morbidity and mortality. The prognosis of adrenocortical cancer (ACC) is poor with an overall five-year survival below 30 %. In this study, CGH analysis was performed on 4 ACC (adrenocortical carcinoma), 4 IA (hormonally inactive adrenocortical adenoma) and 3 CPA (cortisol producing adrenocortical adenoma) samples. Tissue digestion, labeling, hybridization and data analysis of genomic DNA were performed according to the Agilent Technologies (Santa Clara, CA) protocol version 2.0 for 105 K arrays. As expected, many of the observed aberrations were generally consistent with those of other preciously published data and will provide the basis for determination how genomic diversity impacts biological function and human diseases, such as cancer.

2009-08-06 | GSE17396 | GEO

Analysis of circulating microRNAs in adrenocortical tumours

Project description:Differential diagnosis of adrenocortical adenoma and carcinoma is of pivotal clinical relevance, as the prognosis and clinical management of benign and malignant adrenocortical tumours is entirely different. Circulating microRNAs are promising biomarker candidates of malignancy in several tumours. In the present study we investigate circulating microRNAs in adrenocortical tumours and to evaluate their potential applicability as biomarkers of malignancy.

2013-11-19 | GSE49674 | GEO

Deletion of adrenocortical Bmal1 results in sex-biased gene expression.

Project description:We report that deletion of BMAL1 from adrenocortical cells using a SCC(Cyp11a1)-Cre driver reults in elevated plasma corticosterone in female, but not in male mice, following submaximal stress stimulation. RNA sequencing of adrenal glands from control and experimental animals was adopted to identify sex-dependent differences in gene expression that may explain the augmented corticosterone response specifically in female mice.

2019-04-13 | GSE129725 | GEO

Differentially expressed proteins in benign and malignant adrenocortical tumors

Project description:We have compared the microsomal protein fractions from benign and malignant adrenocortical tumors. Protein extracts were trypsinized, peptides separated by HiRIEF (high resolution isoelectric focusing) and analysed by LC-MS.

2014-02-11 | PXD000604 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data